clinical trial · NCT06457503
A Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Participants With Recurrent Metastatic Nasopharyngeal Cancer
Nasopharyngeal Cancer RecurrentToripalimabCisplatinGemcitabineCarboplatin
brief summary
This study aims to investigate toripalimab with chemotherapy in participants with nasopharyngeal cancer.
started
Nov 1, 2024
primary completion
Dec 1, 2027
completion
Dec 1, 2027
last updated
Apr 6, 2026
detailed description
The primary objective of this study is to evaluate the efficacy of toripalimab in combination with chemotherapy (cisplatin and gemcitabine), as measured by objective response rate (ORR) assessed by a Blinded Independent Central Review Committee (BICR) according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 in first-line recurrent metastatic nasopharyngeal cancer participants (both Epstein-Barr virus (EBV) and non-EBV-associated).
official title
Single-Arm Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Recurrent Metastatic Nasopharyngeal Carcinoma Systemic Treatment Naïve Participants
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol